scholarly journals Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction

2020 ◽  
Vol 10 (5) ◽  
pp. 1580-1603 ◽  
Author(s):  
Roberto J. Bernardo ◽  
Francois Haddad ◽  
Etienne J. Couture ◽  
Georg Hansmann ◽  
Vinicio A. de Jesus Perez ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Arterial Hypertension ◽  
Ejection Fraction ◽  
Arterial Hypertension ◽  
Right Ventricular ◽  
Ventricular Dysfunction ◽  
Right Ventricular Dysfunction ◽  
Preserved Ejection Fraction ◽  
Pulmonary Arterial

scholarly journals Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension

2020 ◽  
Vol 10 (5) ◽  
pp. 1659-1674
Author(s):  
Chakradhari Inampudi ◽  
Ryan J. Tedford ◽  
Anna R. Hemnes ◽  
Georg Hansmann ◽  
Harm-Jan Bogaard ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Right Ventricular ◽  
Ventricular Dysfunction ◽  
Right Ventricular Dysfunction ◽  
Pulmonary Arterial

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction

2021 ◽  
Author(s):  
Marco Guazzi ◽  
Robert Naeije
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Right Ventricular ◽  
Ventricular Dysfunction ◽  
Imaging Techniques ◽  
Treatment Options ◽  
Right Ventricular Dysfunction ◽  
Preserved Ejection Fraction ◽  
Right Heart ◽  
The Right

The health burden of heart failure with preserved ejection fraction is increasingly recognized. Despite improvements in diagnostic algorithms and established knowledge on the clinical trajectory, effective treatment options for heart failure with preserved ejection fraction remain limited, mainly because of the high mechanistic heterogeneity. Diagnostic scores, big data, and phenomapping categorization are proposed as key steps needed for progress. In the meantime, advancements in imaging techniques combined to high-fidelity pressure signaling analysis have uncovered right ventricular dysfunction as a mediator of heart failure with preserved ejection fraction progression and as major independent determinant of poor outcome. This review summarizes the current understanding of the pathophysiology of right ventricular dysfunction in heart failure with preserved ejection fraction covering the different right heart phenotypes and offering perspectives on new treatments targeting the right ventricle in its function and geometry.

scholarly journals In Situ Expression of Bcl-2 in Pulmonary Artery Endothelial Cells Associates with Pulmonary Arterial Hypertension Relative to Heart Failure with Preserved Ejection Fraction

2016 ◽  
Vol 6 (4) ◽  
pp. 551-556 ◽  
Author(s):  
Raymond L. Benza ◽  
Gretchen Williams ◽  
Changgong Wu ◽  
Kelly J. Shields ◽  
Amresh Raina ◽  
...  
Keyword(s):  
Heart Failure ◽  
Endothelial Cells ◽  
Pulmonary Arterial Hypertension ◽  
Ejection Fraction ◽  
Pulmonary Artery ◽  
Arterial Hypertension ◽  
World Health ◽  
Heart Catheterization ◽  
Preserved Ejection Fraction ◽  
Pulmonary Arterial

We have previously reported that pulmonary artery endothelial cells (PAECs) can be harvested from the tips of discarded Swan-Ganz catheters after right heart catheterization (RHC). In this study, we tested the hypothesis that the existence of an antiapoptotic phenotype in PAECs obtained during RHC is a distinctive feature of pulmonary arterial hypertension (PAH; World Health Organization group 1) and might be used to differentiate PAH from other etiologies of pulmonary hypertension. Specifically, we developed a flow cytometry-based measure of Bcl-2 activity, referred to as the normalized endothelial Bcl-2 index (NEBI). We report that higher NEBI values are associated with PAH to the exclusion of heart failure with preserved ejection fraction (HFpEF) and that this simple diagnostic measurement is capable of differentiating PAH from HFpEF without presenting addition risk to the patient. If validated in a larger, multicenter study, the NEBI has the potential to assist physicians in the selection of appropriate therapeutic interventions in the common and dangerous scenario wherein patients present a clinical and hemodynamic phenotype that makes it difficult to confidently differentiate between PAH and HFpEF.

Sign in / Sign up

Export Citation Format

Share Document